NIMM
Financiado
Fluorescence based nano immunoassay IVD platform
Antibody-detection related to disease or to drug monitoring demands novel IVD tests that provide robust, rapid and early- stage diagnostics for improved and early on-set treatments. However, companies developing novel IVD immunoas...
Antibody-detection related to disease or to drug monitoring demands novel IVD tests that provide robust, rapid and early- stage diagnostics for improved and early on-set treatments. However, companies developing novel IVD immunoassays face an important barrier related to reimbursement policy issues when the IVD tests are introduced into national health systems. This barrier discourages many companies from pursuing the development of novel diagnostic tests because the investment necessary to introduce novel IVD tests in the market is hardly matched by the return of the investment. NIMM aims at providing a platform for the development of accurate, sensitive and inexpensive immunoassays for antibody-related conditions using a novel fluorescent nanosensor-based technology. The outcome of the project will pave the way to a commercial product to be sold in the Immunochemistry/Immunoassay segment of the IVD market, currently valued at 15 USD billion. Potential stakeholders in the outcome of NIMM include Public Health authorities and pharmaceutical companies.
ver más
Duración del proyecto: 28 meses
Fecha Inicio: 2019-02-12
Fecha Fin: 2021-06-30
Fecha Fin: 2021-06-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2018-PoC:
ERC Proof of Concept Grant
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
ASOC CENTRO DE INVESTIGACION COOP EN BIO
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
3-4
6M
Perfil tecnológico
TRL
3-4
6M